Matches in UGent Biblio for { <https://biblio.ugent.be/publication/523030#aggregation> ?p ?o. }
Showing items 1 to 37 of
37
with 100 items per page.
- aggregation classification "A1".
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2008".
- aggregation format "application/pdf".
- aggregation hasFormat 523030.bibtex.
- aggregation hasFormat 523030.csv.
- aggregation hasFormat 523030.dc.
- aggregation hasFormat 523030.didl.
- aggregation hasFormat 523030.doc.
- aggregation hasFormat 523030.json.
- aggregation hasFormat 523030.mets.
- aggregation hasFormat 523030.mods.
- aggregation hasFormat 523030.rdf.
- aggregation hasFormat 523030.ris.
- aggregation hasFormat 523030.txt.
- aggregation hasFormat 523030.xls.
- aggregation hasFormat 523030.yaml.
- aggregation isPartOf urn:issn:0896-8608.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin".
- aggregation abstract "Background: Since the introduction of surgical debulking in combination with intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC) with oxaliplatin in our institution, severe hyponatremia (sodium: 126.5 +/- 3.8 mmol/L), hyperglycemia (glucose: 22.37 +/- 4.89 mmol/L), and hyperlactatemia (lactate: 3.17 +/- 1.09 mmol/L) have been observed post HIPEC. This metabolic disorder was not observed in patients in whom cisplatin or mitomycin C was used as a chemotherapeutic drug. Methods: In order to understand the pathophysiology of this finding, an analysis of our data was made. In a first analysis, plasma sodium was corrected for hyperglycemia based on the formula of Hillier. In a second analysis, the influence of total exchangeable sodium, total exchangeable potassium, and total body water on plasma sodium concentration was modeled. Results: Analysis of our data revealed a double mechanism for the observed metabolic disorder: hyperglycemia caused by dextrose 5%, which is used as a carrier for the oxaliplatin, and major loss of sodium into the dialysate (256.7 +/- 68.7 mmol). Conclusion: Better control of hyperglycemia and intravenous compensation of sodium loss into the dialysate can attenuate the reported biochemical disturbance.".
- aggregation authorList BK450592.
- aggregation endPage "66".
- aggregation issue "1".
- aggregation startPage "61".
- aggregation volume "25".
- aggregation aggregates 531064.
- aggregation isDescribedBy 523030.
- aggregation similarTo LU-523030.